|
|
 Previous Article | Table of Contents | Next Article 
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor
JY Blay, N Burdin, F Rousset, G Lenoir, P Biron, T Philip, J Banchereau and MC Favrot
Departement de Chimiotherapie Intensive et de Pediatrie, Centre Leon
Berard, Lyon, France.
Serum interleukin-10 (IL-10) was measured retrospectively in 153 patients
with a fully documented history of non-Hodgkin's lymphoma (NHL) using an
enzyme-linked immunosorbent assay (ELISA) detecting both human IL-10 and
the Epstein-Barr virus (EBV) molecule BCRF1/viral IL- 10. IL-10 was
detectable in 47 (46%) of the 101 patients with active NHL, 3 of 52 (6%)
patients in first partial or complete response, and none of the 60 healthy
blood donors. Serum IL-10 was detectable with a similar frequency in all
subtypes of NHL and in all clinical stages, as well as in EBV-seropositive
and EBV-negative patients. In patients with intermediate or high-grade NHL,
the presence of detectable serum IL-10 at diagnosis was correlated to a
significantly shorter overall (P = .025) and progression-free (P = .030)
survival. Patients with stage IV disease and detectable serum IL-10 had a
particularly poor prognosis (4 years of survival: 0%). Multivariate
analysis showed that IL-10 was an independent prognosis factor. These
results indicate that IL-10 is detectable in a subgroup of patients with
active NHL and correlates to a poor survival in patients with intermediate
or high-grade NHL.
Volume 82,
Issue 7,
pp. 2169-2174,
10/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Th. Petridou, T. N. Sergentanis, N. Dessypris, I. T. Vlachantoni, S. Tseleni-Balafouta, A. Pourtsidis, M. Moschovi, S. Polychronopoulou, F. Athanasiadou-Piperopoulou, M. Kalmanti, et al.
Serum Adiponectin As a Predictor of Childhood Non-Hodgkin's Lymphoma: A Nationwide Case-Control Study
J. Clin. Oncol.,
October 20, 2009;
27(30):
5049 - 5055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Blood,
October 1, 2008;
112(7):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kube, T.-D. Hua, F. von Bonin, N. Schoof, S. Zeynalova, M. Kloss, D. Gocht, B. Potthoff, M. Tzvetkov, J. Brockmoller, et al.
Effect of Interleukin-10 Gene Polymorphisms on Clinical Outcome of Patients with Aggressive Non-Hodgkin's Lymphoma: An Exploratory Study
Clin. Cancer Res.,
June 15, 2008;
14(12):
3777 - 3784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Robson, D. J. Phillips, T. McAlpine, A. Shin, S. Svobodova, T. Toy, V. Pillay, N. Kirkpatrick, D. Zanker, K. Wilson, et al.
Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production
Blood,
March 1, 2008;
111(5):
2733 - 2743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Lan, T. Zheng, N. Rothman, Y. Zhang, S. S. Wang, M. Shen, S. I. Berndt, S. H. Zahm, T. R. Holford, B. Leaderer, et al.
Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma
Blood,
May 15, 2006;
107(10):
4101 - 4108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos and D. Morgensztern
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
995 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Flano, B. Kayhan, D. L. Woodland, and M. A. Blackman
Infection of Dendritic Cells by a {gamma}2-Herpesvirus Induces Functional Modulation
J. Immunol.,
September 1, 2005;
175(5):
3225 - 3234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gururajan, R. Chui, A. K. Karuppannan, J. Ke, C. D. Jennings, and S. Bondada
c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells
Blood,
August 15, 2005;
106(4):
1382 - 1391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Tozzi Spinardi-Barbisan, L. F. Barbisan, J. Lauro Viana De Camargo, and M. Aparecida Marchesan Rodrigues
Infiltrating CD8+ T Lymphocytes, Natural Killer Cells, and Expression of IL-10 and TGF-{beta}1 in Chemically Induced Neoplasms in Male Wistar Rats
Toxicol Pathol,
August 1, 2004;
32(5):
548 - 557.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Lech-Maranda, L. Baseggio, J. Bienvenu, C. Charlot, F. Berger, D. Rigal, K. Warzocha, B. Coiffier, and G. Salles
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma
Blood,
May 1, 2004;
103(9):
3529 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sredni, M. Weil, G. Khomenok, I. Lebenthal, S. Teitz, Y. Mardor, Z. Ram, A. Orenstein, A. Kershenovich, S. Michowiz, et al.
Ammonium Trichloro(dioxoethylene-o,o')tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop
Cancer Res.,
March 1, 2004;
64(5):
1843 - 1852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asadullah, W. Sterry, and H. D. Volk
Interleukin-10 Therapy--Review of a New Approach
Pharmacol. Rev.,
June 1, 2003;
55(2):
241 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Brown, B. Pope, A. Murray, W. Esdale, D. M. Sze, J. Gibson, P. J. Ho, D. Hart, and D. Joshua
Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta 1 and interleukin-10
Blood,
November 15, 2001;
98(10):
2992 - 2998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Alas and B. Bonavida
Rituximab Inactivates Signal Transducer and Activation of Transcription 3 (STAT3) Activity in B-Non-Hodgkin's Lymphoma through Inhibition of the Interleukin 10 Autocrine/Paracrine Loop and Results in Down-Regulation of Bcl-2 and Sensitization to Cytotoxic Drugs
Cancer Res.,
July 1, 2001;
61(13):
5137 - 5144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Alas, C. Emmanouilides, and B. Bonavida
Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin's Lymphoma to Apoptosis
Clin. Cancer Res.,
March 1, 2001;
7(3):
709 - 723.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. Fayad, M. J. Keating, J. M. Reuben, S. O'Brien, B.-N. Lee, S. Lerner, and R. Kurzrock
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome
Blood,
January 1, 2001;
97(1):
256 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. K. Akpek, C. S. Foster, R. R. Buggage, S. M. Whitcup, R. B. Nussenblatt, and C.-C. Chan
Primary Intraocular Lymphoma With a Low Interleukin 10 to Interleukin 6 Ratio and Heterogeneous IgH Gene Arrangement
Arch Ophthalmol,
May 1, 2000;
118(5):
731 - 732.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. De Vita, M. Orditura, G. Galizia, C. Romano, A. Roscigno, E. Lieto, and G. Catalano
Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients
Chest,
February 1, 2000;
117(2):
365 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Kossakowska, D. R. Edwards, C. Prusinkiewicz, M. C. Zhang, D. Guo, S. J. Urbanski, T. Grogan, L. A. Marquez, and A. Janowska-Wieczorek
Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non-Hodgkin's Lymphomas
Blood,
September 15, 1999;
94(6):
2080 - 2089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D de Smet, V. S. Vancs, D. Kohler, D. Solomon, and C. C. Chan
Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma
Br J Ophthalmol,
April 1, 1999;
83(4):
448 - 451.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Menetrier-Caux, G. Montmain, M.C. Dieu, C. Bain, M.C. Favrot, C. Caux, and J.Y. Blay
Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor
Blood,
December 15, 1998;
92(12):
4778 - 4791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Voorzanger-Rousselot, M.-C. Favrot, and J.-Y. Blay
Resistance to Cytotoxic Chemotherapy Induced by CD40 Ligand in Lymphoma Cells
Blood,
November 1, 1998;
92(9):
3381 - 3387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nicolaides, S. Dimou, and N. Pavlidis
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas
Oncologist,
June 1, 1998;
3(3):
189 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. M. Dorfman, J. L. Schultze, A. Shahsafaei, S. Michalak, J. G. Gribben, G. J. Freeman, G. S. Pinkus, and L. M. Nadler
In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation
Blood,
December 1, 1997;
90(11):
4297 - 4306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Whitcup, V. Stark-Vancs, R. E. Wittes, D. Solomon, M. J. Podgor, R. B. Nussenblatt, and C.-C. Chan
Association of Interleukin 10 in the Vitreous and Cerebrospinal Fluid and Primary Central Nervous System Lymphoma
Arch Ophthalmol,
September 1, 1997;
115(9):
1157 - 1160.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Jiang, H. N. Ananthaswamy, H. K. Muller, A. Ouhtit, S. Bolshakov, S. E. Ullrich, A. K. El-Naggar, and M. L. Kripke
UV irradiation augments lymphoid malignancies in mice with one functional copy of wild-type p53
PNAS,
August 14, 2001;
98(17):
9790 - 9795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
